HIV Vaccine for HIV Infection
(NETI Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a new vaccine called Trimer 4571 to see if it can help people with HIV by making their immune system produce special proteins that fight the virus. The study will involve about 32 participants over several months. Researchers aim to find out if the vaccine is safe and effective in boosting the body's defense against HIV.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you must have been on a stable antiretroviral therapy (ART) for at least 8 weeks before joining. You cannot use certain medications like systemic immunomodulators or investigational therapies within 60 days before the study.
What data supports the effectiveness of the treatment Trimer 4571 Therapeutic Vaccination, Trimer 4571, BG505 DS-SOSIP.664 for HIV infection?
Is the Trimer 4571 HIV vaccine safe for humans?
What makes the Trimer 4571 therapeutic vaccination unique compared to other HIV treatments?
Trimer 4571, also known as BG505 DS-SOSIP.664, is unique because it uses a stabilized HIV-1 envelope protein trimer to elicit broadly neutralizing antibodies, which are crucial for effective immune response against diverse HIV strains. This approach focuses on inducing a strong and broad immune response, unlike traditional treatments that primarily manage the virus rather than prevent infection.1351112
Eligibility Criteria
Adults over 18 living with HIV on stable antiretroviral therapy (ART) for at least 24 months, with undetectable viral loads and no history of severe allergies or chronic inflammatory conditions. Participants must not be pregnant, breastfeeding, or have a BMI over 40kg/m2, and should agree to use contraception during the trial.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive the Trimer 4571 vaccine or placebo at Day 0, Week 8, and Week 20
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Trimer 4571 Therapeutic Vaccination (Cancer Vaccine)